Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification – Gerhardt Attard
Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. They explore the use of the Decipher® genomic classifier as a prognostic and predictive tool for treatment decisions in metastatic prostate cancer. The conversation covers the test’s ability to identify patients who are likely to benefit from abiraterone and,…